RheumShorts: Triple Therapy, Q Fever, and Etanercept (CME/CE)
(MedPage Today) -- Dutch researchers weighed in this week about triple therapy for rheumatoid arthritis, the dangers of Q fever for patients with RA, and the implications of serum levels of etanercept (Enbrel) for patients with ankylosing spondylitis. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 8, 2014 Category: Geriatrics Source Type: news
Lower Enbrel Dose Cuts Efficacy in Spine Disease
LIVERPOOL (MedPage Today) -- Decreasing the weekly dose of etanercept (Enbrel) from 50 mg to 25 mg among patients with ankylosing spondylitis was less effective than maintaining the standard dose, a researcher reported here. (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - May 1, 2014 Category: Anesthesiology Source Type: news
Lupin forms Joint Venture with Japan's Yoshindo Inc
Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical development to YLB. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 24, 2014 Category: Pharmaceuticals Source Type: news
Treatment of RA With Etanercept With Reference to DMARDsTreatment of RA With Etanercept With Reference to DMARDs
This study compares the long-term safety of etanercept with conventional DMARDs. Rheumatology (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 9, 2014 Category: Rheumatology Tags: Rheumatology Journal Article Source Type: news
Oral Tofacitinib Not Inferior to Etanercept for PsoriasisOral Tofacitinib Not Inferior to Etanercept for Psoriasis
The oral small-molecular inhibitor could be a viable option for psoriasis patients who don't want to use an injectable drug. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 26, 2014 Category: Consumer Health News Tags: Dermatology News Source Type: news
Low Disease Activity Predicts Good Response in CAMEO TrialLow Disease Activity Predicts Good Response in CAMEO Trial
Patients with RA who achieve low disease activity or remission after 6 months on etanercept plus methotrexate continue to have stable disease out to 12 and even 24 months on etanercept alone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Methotrexate Alone OK in Early Arthritis
(MedPage Today) -- Monotherapy with methotrexate was as effective as methotrexate plus etanercept (Enbrel) in patients with early inflammatory arthritis, although the combination resulted in faster response, U.K. researchers reported. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 14, 2014 Category: Geriatrics Source Type: news
Epidural Etanercept for Symptomatic Lumbar Disc HerniationEpidural Etanercept for Symptomatic Lumbar Disc Herniation
Epidural etanercept may be a safe and effective therapeutic option for patients with sciatica associated with symptomatic lumbar disc herniation. Spine (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 9, 2013 Category: Orthopaedics Tags: Orthopaedics Journal Article Source Type: news
Etanercept Challenges Cortisone as Treatment for Sciatica
A new randomized, controlled trial(RCT) is the fourth RCT to provide evidence for the efficacy of etanercept for intervertebral disc-related pain. The first human data regarding the effectiveness of...(PRWeb November 07, 2013)Read the full story at http://www.prweb.com/releases/2013/11/prweb11305858.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 10, 2013 Category: Pharmaceuticals Source Type: news
Certain Rheumatoid Arthritis Drugs May Also Protect Patients' Hearts, Studies Find
Biologic drugs such as Enbrel, Humira may lower rate of heart attack, researchers say (Source: WebMD Health)
Source: WebMD Health - October 26, 2013 Category: Consumer Health News Source Type: news
Certain Rheumatoid Arthritis Drugs May Also Protect Patients' Hearts, Studies Find
Biologic drugs such as Enbrel, Humira may lower rate of heart attack, researchers say
Source: HealthDay
Related MedlinePlus Pages: Heart Diseases--Prevention, Medicines, Rheumatoid Arthritis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 26, 2013 Category: Consumer Health News Source Type: news
TNF Blockade Eases Eye Disease in Kids (CME/CE)
(MedPage Today) -- Children with chronic autoimmune uveitis showed favorable responses to treatment with either adalimumab (Humira) or infliximab (Remicade), although not with etanercept (Enbrel), a meta-analysis found. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - October 24, 2013 Category: Pediatrics Source Type: news
Pfizer drug shows mixed results in psoriasis trials
(Reuters) - A high dose of Pfizer Inc's drug, tofacitinib, proved as effective as the widely used treatment, Enbrel, in treating adults with moderate-to-severe psoriasis in a late-stage study , while a lower dose of tofacitinib was less effective than Enbrel, the drugmaker said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - October 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Secukinumab showed superior efficacy over etanercept in clearing skin, according to pivotal Novartis Phase III psoriasis results presented at EADV
Novartis has nnounced the results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, showed superior efficacy to etanercept in moderate-to-severe plaque psoriasis1. Etanercept is a NICE-approved anti-tumour necrosis factor (anti-TNF) therapy, used to treat moderate-to-severe plaque psoriasis2. These significant results are being presented today at the 22nd Congress of the European Association of Dermatology and Venereology (EADV) in Istanbul, Turkey1... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 7, 2013 Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news
Pivotal Novartis Phase III psoriasis results at EADV
Novartis has announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 3, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Dermatology Latest News Source Type: news
